Veracyte | VCYT - Equity Capital And Reserves


Veracyte reported $1.34B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Agenus USD -221.22M 49.89M Mar/2026
Agilent USD 7.12B 214M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
Bruker USD 2.46B 35.9M Dec/2025
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Illumina USD 2.68B 47M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Laboratory Of America USD 8.73B 108.8M Mar/2026
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
Myriad Genetics USD 337.4M 30.6M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Siemens EUR 64.39B 1.09B Mar/2026
Sonic Healthcare AUD 8.2B 120.9M Dec/2024
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Veracyte USD 1.34B 34.83M Mar/2026
Waters USD 2.56B 230.55M Dec/2025